HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 387 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,445 | +28.7% | 27,600 | 0.0% | 0.05% | +25.0% |
| Q1 2024 | $1,123 | +10.1% | 27,600 | 0.0% | 0.04% | +2.6% |
| Q4 2023 | $1,020 | -3.2% | 27,600 | 0.0% | 0.04% | -13.3% |
| Q3 2023 | $1,054 | +5.8% | 27,600 | 0.0% | 0.04% | +2.3% |
| Q2 2023 | $996 | +6.4% | 27,600 | +12.7% | 0.04% | -6.4% |
| Q1 2023 | $936 | -24.2% | 24,500 | +12.9% | 0.05% | -28.8% |
| Q4 2022 | $1,235 | -99.9% | 21,700 | 0.0% | 0.07% | +40.4% |
| Q3 2022 | $858,000 | -10.2% | 21,700 | 0.0% | 0.05% | +2.2% |
| Q2 2022 | $955,000 | -9.3% | 21,700 | -17.8% | 0.05% | +17.9% |
| Q1 2022 | $1,053,000 | -0.8% | 26,400 | 0.0% | 0.04% | +8.3% |
| Q4 2021 | $1,062,000 | -1.1% | 26,400 | 0.0% | 0.04% | -2.7% |
| Q3 2021 | $1,074,000 | -10.4% | 26,400 | 0.0% | 0.04% | -9.8% |
| Q2 2021 | $1,199,000 | +27.8% | 26,400 | +17.3% | 0.04% | +10.8% |
| Q1 2021 | $938,000 | -2.4% | 22,500 | 0.0% | 0.04% | -9.8% |
| Q4 2020 | $961,000 | – | 22,500 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
| BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
| DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
| SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
| First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
| Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
| Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
| Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |